Richter Gedeon Nyrt
Richter Gedeon Nyrt. is a Hungary-headquartered, vertically integrated specialty pharmaceutical company (founded 1901) that manufactures 200+ drugs across neuropsychiatry, women's healthcare, biosimilars, and general medicines, selling in 100+ countries with HUF 914B FY2025 revenue.
- Company typePublic
- Founded1901
- HeadquartersBudapest, Hungary
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Richter Gedeon Nyrt does
Richter Gedeon Nyrt. is a Hungary-headquartered, vertically integrated specialty pharmaceutical company founded in 1901 by pharmacist Gedeon Richter, listed on the Budapest Stock Exchange as a leading blue-chip. The company manufactures more than 200 drugs (originals, generics, and licensed products) across four business units: Neuropsychiatry (anchored by cariprazine/Reagila), Biotechnology (biosimilars and CDMO services through Richter BioLogics), Women's Healthcare (contraception, fertility, endometriosis, menopause, uterine fibroids, HRT), and General Medicines (cardiometabolic, CNS, rheumatology generics). It operates with 12,000+ employees, of which 1,200+ are in R&D — the largest pharmaceutical research centre in Central Eastern Europe — spending over 7% of revenue on R&D and leveraging in-house active ingredient manufacturing and internationally recognised steroid chemistry expertise.
The company sells through direct subsidiaries and representative offices in 100+ countries across Europe, CIS, Americas, Asia-Pacific, and Oceania, complemented by channel partnerships (Hikma for US biosimilars, Hetero Labs for Semaglutide in US and emerging markets, Acrux for Lenzetto in Australia, AbbVie co-development for neuropsychiatry). FY2025 revenue reached HUF 914 billion (~EUR 2.3 billion) with 14% clean EBIT growth, and FY2026 guidance points to high single-digit revenue growth. Recent strategic activity is heavily concentrated on portfolio expansion in women's healthcare (Celmatix acquisition, FimmCyte FMC2 collaboration) and entry into GLP-1 therapeutics (Semaglutide partnership with Hetero), alongside biosimilar approvals such as Tuyory's CHMP positive opinion. The company also offers CDMO services for biologics and runs a biosimilar licensing business that monetises its manufacturing scale through partners like Hikma.
Richter Gedeon Nyrt firmographics
Firmographics- Name
- Richter Gedeon Nyrt
- Legal name
- Richter Gedeon Vegyészeti Gyár Nyilvánosan Működő Rt.
- Website
- https://gedeonrichter.com
- Company type
- Public
- Founded year
- 1901
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Richter Gedeon Nyrt. is a Hungary-headquartered, vertically integrated specialty pharmaceutical company (founded 1901) that manufactures 200+ drugs across neuropsychiatry, women's healthcare, biosimilars, and general medicines, selling in 100+ countries with HUF 914B FY2025 revenue.
- Ownership category
- akta.pro rank
Richter Gedeon Nyrt industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Richter Gedeon Nyrt is headquartered
LocationHeadquarters
- HQ city
- Budapest
- HQ country
- Hungary
- HQ region
- Europe
Offices18 records
Markets served
Richter Gedeon Nyrt business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Richter generates revenue primarily through the manufacture and sale of pharmaceutical products including original, generic, and licensed drugs across CNS, cardiovascular, gynaecological, and general medicine therapeutic areas. The company manufactures more than 200 drugs sold in 100+ countries through direct subsidiaries and distribution partners.
- Licensed and Co-Development Products: Revenue from licensed products (e.g., Lenzetto transdermal estradiol spray licensed to Acrux for Australia, Reagila schizophrenia treatment acquired from Recordati), and co-development partnerships including global collaboration with Hetero Labs for Semaglutide and partnership with AbbVie for neuropsychiatric treatments.
- CDMO / Contract Manufacturing Services: Through its biotechnology business unit, Richter offers contract development and manufacturing (CDMO) services for biosimilars and biologic products, including manufacturing denosumab biosimilars for Hikma under a 2021 license and commercialization agreement.
- Biosimilar Licensing: Revenue from out-licensing biosimilar products developed and manufactured by Richter, with Hikma holding exclusive US commercialization rights for denosumab biosimilars Enoby and Xtrenbo.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Prescription pharmaceutical products sold through pharmacies and healthcare providers |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels4 records
Richter Gedeon Nyrt product offering
Product offeringCore offering
Richter Gedeon Nyrt is a vertically integrated specialty pharmaceutical company that manufactures and markets more than 200 drugs including original, generic, and licensed products across CNS, cardiovascular, women's healthcare, and biosimilar therapeutic areas. The company operates in-house API manufacturing, conducts original NCE research, runs CDMO services through Richter BioLogics, and distributes products to healthcare providers and patients in 100+ countries through direct subsidiaries and channel partners.
Product overview
Gedeon Richter is a Hungarian-headquartered pharmaceutical company founded in 1901, operating as a vertically integrated specialty pharmaceutical company involved in manufacturing, R&D, sales and marketing. The company manufactures more than 200 drugs including original, generic and licensed products providing effective treatments in central nervous system (CNS), cardiovascular, and gynecological (Women's Healthcare) therapeutic areas. The product portfolio is organized around four main business units: Neuropsychiatry (led by Cariprazine/Reagila), Biotechnology (including CDMO services and biosimilars), Women's Healthcare (spanning contraception, fertility, endometriosis, menopause, uterine fibroids, vaginal infections, and HRT), and General Medicines (generic medications for cardiometabolic, CNS, and rheumatology). The company's strategy emphasizes original research, women's healthcare, and biosimilars, with key products including Cariprazine for schizophrenia, Tuyory (tocilizumab biosimilar), denosumab biosimilars (Enoby/Xtrenbo), Ryeqo, and Lenzetto. Recent portfolio expansion includes acquired assets from Celmatix (fertility/endometriosis/ovarian aging programs) and partnership-enabled products like the Semaglutide generic (with Hetero Labs) and FMC2 (with FimmCyte).
Differentiator
Problem solved
Functional benefit
Brands
- Enoby: Denosumab biosimilar referencing Amgen's Prolia, manufactured by Gedeon Richter under Hikma license for US market.
- Xtrenbo
Products and services
- Cariprazine (Reagila) Cariprazine is an original research compound developed by Gedeon Richter for the treatment of central nervous system disorders, including schizophrenia and bipolar disorder. Marketed as Reagila in multiple markets.
- Lenzetto (transdermal estradiol spray) Transdermal estradiol spray for menopausal hormone therapy, licensed to Acrux Limited for distribution in Australia and additional territories.
- Tuyory (tocilizumab biosimilar) Richter's own biosimilar tocilizumab product, branded Tuyory, intended for multiple indications corresponding to the originator biologic. Received positive CHMP opinion in 2026.
- Enoby (denosumab biosimilar) Denosumab biosimilar referencing Amgen's Prolia for osteoporosis treatment, manufactured by Gedeon Richter and commercialized in the US by Hikma under exclusive US commercialization rights.
- Xtrenbo (denosumab biosimilar) Denosumab biosimilar referencing Amgen's Xgeva for bone cancer-related complications, manufactured by Gedeon Richter and commercialized in the US by Hikma.
- Ryeqo Combination therapy for symptoms of uterine fibroids and endometriosis in women of reproductive age.
- Biotechnology / CDMO Services Contract development and manufacturing organization (CDMO) services for biosimilars and biological drugs, delivered through Richter BioLogics GmbH in Hamburg, covering development, manufacture, and commercialization support for biologic products.
Quantifiable outcome
- 14% growth in clean EBIT in fiscal year 2025
- +1 more outcomes
Companies that use Richter Gedeon Nyrt
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Richter Gedeon Nyrt technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Richter Gedeon Nyrt partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Hetero Labs Ltd.coreGlobal collaboration agreement between Gedeon Richter and India-based Hetero Labs for the joint development, registration, and commercialization of Semaglutide Injection (generic version of Ozempic). The partnership combines Hetero's market reach in the US and emerging markets with Richter's commercial network across Europe and Central Asia under a cost- and profit-sharing model. Regulatory filings are planned for 2027 in the EU and US.
- Acrux LimitedminorGedeon Richter and Acrux Limited extended the license agreement dated 2 May 2013 relating to the transdermal Estradiol spray Lenzetto (menopause hormone therapy) to cover an additional commercially significant territory.
- CelmatixcoreRichter acquired the women's health drug discovery portfolio from US biotech Celmatix, adding three early-stage programs spanning fertility, endometriosis, and ovarian aging to its pipeline. Celmatix receives upfront and milestone payments as development progresses. The deal signals ovarian biology emerging as an investable area within longevity science.
- FimmCytecoreSwiss biotech FimmCyte entered a strategic research collaboration and option-to-license agreement with Gedeon Richter to advance its first-in-class, non-hormonal antibody treatment FMC2 for endometriosis. Joint R&D toward first-in-human clinical studies with Richter holding an exclusive option on global rights exercisable before first clinical trial. Richter operates Central Europe's largest R&D hub. FimmCyte eligible for development and commercial milestone payments plus tiered royalties.
- Recordati PharmaceuticalsminorGedeon Richter UK acquired rights to the schizophrenia treatment Reagila from Recordati Pharmaceuticals, expanding the CNS portfolio in the UK market.
- AbbViecoreAbbVie entered a co-development agreement with Gedeon Richter for novel neuropsychiatric treatments, expanding Richter's CNS pipeline through strategic partnership with a major global pharmaceutical company.
- Hikma PharmaceuticalscoreUK-headquartered Hikma Pharmaceuticals and its US subsidiary launched two denosumab biosimilars (Enoby and Xtrenbo) in the US market, referencing Amgen's Prolia and Xgeva. Products are manufactured by Gedeon Richter under a 2021 license and commercialization agreement, with Hikma holding exclusive US commercialization rights.
- Judit PolgárminorLong-standing partnership between Gedeon Richter and chess legend Judit Polgár, demonstrated at Chessparty Stockholm (April 17-18 at Avicii Arena). The partnership draws parallels between elite chess and business leadership, with thousands of children and young people attending to play chess and meet role models. Mats Jonsson, Manager of Gedeon Richter Nordics, represented the company at the event.
- Semmelweis UniversityminorThe Semmelweis-Richter Journalism Award 2026, jointly awarded by Semmelweis University and Gedeon Richter, recognises outstanding journalism on health topics in Europe. Total prize of 45,000 EUR across two categories (Women's Health and Pharma Strategies and Innovation). Winners to be announced in the last week of July 2026.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Richter Gedeon Nyrt competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Richter Gedeon Nyrt social profiles
Digital presenceRichter Gedeon Nyrt financial estimates
Financial estimateRevenue estimate
Valuation estimate
Richter Gedeon Nyrt leadership team
Management profileNumber of profiles
Profiles7 records
Richter Gedeon Nyrt subsidiaries and ownership
Company hierarchySubsidiaries44 records
Richter Gedeon Nyrt funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Richter Gedeon Nyrt M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Richter Gedeon Nyrt
What does Richter Gedeon Nyrt do?
Richter Gedeon Nyrt is a vertically integrated specialty pharmaceutical company that manufactures and markets more than 200 drugs including original, generic, and licensed products across CNS, cardiovascular, women's healthcare, and biosimilar therapeutic areas. The company operates in-house API manufacturing, conducts original NCE research, runs CDMO services through Richter BioLogics, and distributes products to healthcare providers and patients in 100+ countries through direct subsidiaries and channel partners.
Is Richter Gedeon Nyrt a public or private company?
Richter Gedeon Nyrt is a public company. It is classified as public and is currently operating.
When was Richter Gedeon Nyrt founded?
Richter Gedeon Nyrt was founded in 1901. It employs 5,001 to 10,000 people.
Where is Richter Gedeon Nyrt based?
Richter Gedeon Nyrt is headquartered in Budapest, Hungary, in the Europe region.
How does Richter Gedeon Nyrt make money?
Four revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensed and Co-Development Products, CDMO / Contract Manufacturing Services and biosimilar Licensing.
Does Richter Gedeon Nyrt have an API?
No public API is recorded for Richter Gedeon Nyrt.
What industry is Richter Gedeon Nyrt in?
Richter Gedeon Nyrt's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 32541 and its SIC code is 2834.